Suppr超能文献

三项欧洲上皮性卵巢癌病例对照研究的汇总分析:III. 口服避孕药的使用情况

Pooled analysis of 3 European case-control studies of epithelial ovarian cancer: III. Oral contraceptive use.

作者信息

Franceschi S, Parazzini F, Negri E, Booth M, La Vecchia C, Beral V, Tzonou A, Trichopoulos D

机构信息

Epidemiology Unit, Aviano Cancer Center, Italy.

出版信息

Int J Cancer. 1991 Aug 19;49(1):61-5. doi: 10.1002/ijc.2910490112.

Abstract

The relationship between use of oral contraceptives (OCs) and other contraceptive methods and the risk of ovarian cancer was examined in a combined analysis of 3 hospital-based case-control studies conducted in Italy, the United Kingdom, and Greece, for a total of 971 ovarian cancer cases and 2,258 controls under age 65. Compared with never-users, the combined multivariate relative risk (RR) for ever-users was 0.6 (95% confidence interval, CI = 0.4-0.8) and the estimates were consistent in the 3 datasets. The protection was also similar across strata of age and parity. Considering various measures of OC use, available in the Italian and British datasets only, the protection conveyed on ovarian cancer risk increased with the duration of use and persisted in the medium-long period: the RR in women reporting their last OC use greater than or equal to 15 years prior to diagnosis was 0.5 (95% CI = 0.2-1.0). The risks in ever-users were appreciably lower in those women who reported their first OC use before 25 years of age (RR = 0.3 for first use before age 25, 0.8 for first use at age 25-34 and 0.7 at 35 years or after). Such findings emerged similarly from Italian and British data. This combined analysis, besides offering further quantitative estimates of the protective effects of OCs on ovarian cancer risk in European populations, provides useful insights into the time pattern of the relationship between OC use and ovarian carcinogenesis, suggesting that the protection persists for 15 years or more after cessation of use and may be larger for use at younger age.

摘要

在一项对意大利、英国和希腊开展的3项基于医院的病例对照研究的综合分析中,研究了口服避孕药(OCs)及其他避孕方法的使用与卵巢癌风险之间的关系,该分析共纳入了971例卵巢癌病例和2258例65岁以下对照。与从未使用者相比,曾经使用者的综合多变量相对风险(RR)为0.6(95%置信区间,CI = 0.4 - 0.8),且在3个数据集中的估计结果一致。在年龄和产次分层中,这种保护作用也相似。仅考虑意大利和英国数据集中提供的OC使用的各种测量指标,对卵巢癌风险的保护作用随使用时间延长而增加,并在中长期持续存在:报告最后一次使用OC在诊断前15年及以上的女性的RR为0.5(95%CI = 0.2 - 1.0)。在25岁之前首次使用OC的女性中,曾经使用者的风险明显更低(25岁之前首次使用的RR = 0.3,25 - 34岁首次使用的RR = 0.8,35岁及以后首次使用的RR = 0.7)。意大利和英国的数据也得出了类似的结果。这项综合分析除了对欧洲人群中OC对卵巢癌风险的保护作用提供进一步的定量估计外,还对OC使用与卵巢癌发生之间关系的时间模式提供了有用的见解,表明在停止使用后保护作用持续15年或更长时间,且在年轻时使用可能更大。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验